Literature DB >> 25029981

Introduction to a supplement on innovative approaches to studying health outcomes in rare diseases.

Aaron S Kesselheim1, Joshua J Gagne.   

Abstract

Mesh：

Year:  2014        PMID： 25029981      PMCID： PMC4124123          DOI： 10.1007/s11606-014-2921-y

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  5 in total

1.  Personalized medicine in cystic fibrosis: dawning of a new era.

Authors:  John P Clancy; Manu Jain
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

2.  Orphan products: an emerging trend in drug approvals.

Authors:  Timothy Coté; Aditya Kelkar; Kui Xu; M Miles Braun; M Ian Phillips
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 3.  An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.

Authors:  Aaron S Kesselheim
Journal:  Milbank Q       Date:  2011-09       Impact factor: 4.911

4.  Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.

Authors:  Roberta Joppi; Vittorio Bertele'; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

5.  Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.

Authors:  Aaron S Kesselheim; Jessica A Myers; Jerry Avorn
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272
  5 in total
  1 in total

1.  Innovative approaches to studying health outcomes in rare diseases.

Authors:  William R Phillips
Journal:  J Gen Intern Med       Date:  2015-01       Impact factor: 5.128
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.